NCT06929273
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 33 versions: 33 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 182 → 191 locations
- Notable Eligibility criteria expanded, about 15 words
- Study sites: 182 to 184
- Minor Trial sites expanded: 174 → 182 locationsv31
- Minor Study sites revised (174)v30
- Notable Eligibility criteria expanded, about 3 words
- Study sites: 175 to 174
- Minor Trial sites expanded: 172 → 175 locationsv28
- Minor Study sites: 173 to 172v27
- Minor Study sites: 172 to 173v26
- Minor Study sites: 170 to 172v25
- Minor Study sites revised (170)v24
- Minor Study sites revised (170)v23
- Minor Study sites: 169 to 170v22
- Minor Study sites: 170 to 169v21
- Minor Study sites revised (170)v20
- Minor Study sites: 169 to 170v19
- Minor Study sites: 157 to 169v18
- Minor Study sites: 153 to 157v17
- Minor Study sites revised (153)v16
- Minor Study sites: 152 to 153v15
- Minor Study sites: 143 to 152v14
- Minor Study sites revised (143)v13
- Minor Study sites: 141 to 143v12
Notable Enrollment target: 300 to 450v11 Show 4 more changesShow less
- Eligibility criteria expanded, about 5 words
- Interventions: KarXT (Drug) to KarXT (Drug), Lamotrigine (Drug), Lithium (Drug), Valproate (Drug)
- Secondary endpoints revised (8)
- Study sites revised (141)
- Minor Study sites: 129 to 141v10
- Minor Study sites revised (129)v9
- Minor Study sites: 126 to 129v8
- Minor Study sites: 125 to 126v7
- Minor Study sites: 124 to 125v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 123 to 124
- Start date changed from estimate of Jul 22, 2025 to Jul 18, 2025
- Minor Study sites: 122 to 123v4
- Minor Study sites: 119 to 122v3
- Minor Study sites: 110 to 119v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with treatment emergent adverse events (TEAEs)
Timeframe: Up to week 54
Secondary (8)
Number of participants with AEs of special interest (AESIs)
Number of participants with serious AEs (SAEs)
Number of participants with TEAEs leading to treatment discontinuation
Number of participants with change in suicidal ideation as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Change from baseline in Barnes Akathisia Rating Scale (BARS) score
Show 3 moreShow less
Change from baseline in Simpson Angus Scale (SAS) score
Change from baseline in Abnormal Involuntary Movement Scale (AIMS) score
Change from baseline in International Prostate Symptom Score (IPSS)
Arms and interventions
KarXT or Adjuvant KarXTExperimental
Drugs: KarXT, Lithium, Valproate, Lamotrigine
Sites
191 sites in 20 countries
United States 60, Japan 24, China 18, Ukraine 12, India 11, Romania 10, Bulgaria 8, Israel 8, Poland 6, Croatia 5, Italy 5, Argentina 4, France 3, Hungary 3, Slovakia 3, Spain 3, Sweden 3, Australia 2, Denmark 2, New Zealand 1